Expect near-term downside pressure on NSPR as the recall halts U.S. commercialization and guidance withdrawal signals material revenue disruption. Monitor the Q1 2026 earnings call on May 4 for details on recall costs and updated outlook. The IDE approval for SwitchGuard is a positive long-term catalyst but likely insufficient to support the stock in the near term.
Price Chart
Executive Summary
InspireMD initiated a voluntary U.S. recall of its CGuard Prime 135 cm delivery system due to performance issues and withdrew its full-year 2026 revenue guidance, significantly impacting near-term U.S. commercial prospects. The company also announced FDA approval of an IDE for the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system, but this is a long-term positive that does not offset the immediate negative impact of the recall.
Key Facts
- Voluntary U.S. recall of CGuard Prime 135 cm carotid stent delivery system due to technical performance not meeting expectations
- Withdrew prior full-year 2026 revenue guidance due to temporary discontinuation of U.S. commercial activity
- FDA approval of IDE for CGUARDIANS III pivotal study of SwitchGuard NPS for TCAR procedures
- Q1 2026 global unit sales grew 53% YoY and U.S. unit sales grew 34% sequentially
- Expects FDA approval for original CGuard delivery system in Q3 2026 and CGuard Prime 80 cm for TCAR in 2H 2026
Financial Impact
Immediate loss of U.S. commercial sales for CGuard Prime 135 cm until original CGuard approval (expected Q3 2026); recall costs and potential inventory write-offs; no specific dollar amounts provided
Risk Factors
- Recall-related costs (refunds, inventory write-offs, remediation) could strain liquidity
- Potential product liability lawsuits or regulatory actions
- Delay in FDA approval for original CGuard or CGuard Prime 80 cm beyond current expectations
- Loss of customer confidence and market share to competitors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-020891 |
| Exhibit: ex99-1.htm | 0001493152-26-020891 |
| Exhibit: ex99-2.htm | 0001493152-26-020891 |
| Document: 0001493152-26-020891-index-headers.html | 0001493152-26-020891 |
| Document: 0001493152-26-020891-index.html | 0001493152-26-020891 |
| Document: 0001493152-26-020891.txt | 0001493152-26-020891 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4498 (−40.03%) |
Sep 21, 2026 5w ago | Press Release | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4498 (−40.03%) |
Aug 17, 2026 10w ago | 8-K | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4498 (+48.87%) |
Aug 17, 2026 10w ago | Press Release | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4498 (+48.87%) |
Aug 10, 2026 11w ago | Press Release | $0.8500 $0.8816 | ▲ +3.72% | ▲ +4.12% | $0.4498 (−47.08%) |
Jul 29, 2026 12w ago | 8-K | $0.6718 $0.7222 | ▲ +7.50% | ▲ +3.88% | $0.4498 (−33.05%) |
Jul 23, 2026 13w ago | 8-K | $0.6835 $0.6718 | ▲ +1.71% | ▲ +2.09% | $0.4498 (+34.19%) |
Jul 2, 2026 16w ago | 8-K | $0.6990 $0.7121 | ▲ +1.87% | ▲ +0.94% | $0.4498 (−35.65%) |
May 21, 2026 22w ago | Insider Cluster | $1.00 $0.9900 | ▼ −1.00% | ▼ −2.66% | $0.4498 (−55.02%) |
May 15, 2026 23w ago | Insider Cluster | $1.05 $0.9500 | ▼ −9.52% | ▼ −11.14% | $0.4498 (−57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers